Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 107-118

  Makinde, Adeola Y ^a   Luo Owen, Xian ^a   Rizvi, Asma ^a   Crapo, James D ^b   Pearlstein, Robert D ^c   Slater, James M ^a   Gridley, Daila S ^a,d  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cells; Cytokines; Immune system; Ionizing radiation; NK cells; RM 9 prostate cancer; SOD mimetic

Indexed keywords

ANTIOXIDANT; HEMOGLOBIN; INTERLEUKIN 2; MANGANESE TETRAKIS(N ETHYLPYRIDINIUM 2 YL)PORPHYRIN; METALLOPORPHYRIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ERYTHROCYTE COUNT; FOLLOW UP; HELPER CELL; HEMATOCRIT; LEUKOCYTE COUNT; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION RESPONSE; TUMOR GROWTH;

ANIMALS; ANTIOXIDANTS; BLOOD PLATELETS; BODY WEIGHT; DISEASE MODELS, ANIMAL; ERYTHROCYTES; INTERLEUKIN-2; LEUKOCYTES; LYMPHOCYTE SUBSETS; MALE; METALLOPORPHYRINS; MICE; MICE, INBRED C57BL; ORGAN SIZE; PROSTATIC NEOPLASMS; RADIATION-PROTECTIVE AGENTS; SPLEEN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 61449210082     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Storey MR, Pollack A, Zagars G, Smith L, Antolak J and Rosen I: Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48: 635-642, 2000.
2. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH and Semenza GL: Expression of hypoxia-inducible factor-1{alpha}: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
3. Koli K, Myllarniemi M, Keski-Oja J and Kinnula VL: Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 10: 333-342, 2008.
4. Jobling MF, Mott JD, Finnegan MT, Jurukovski V, Erickson AC, Walian PJ, Taylor SE, Ledbetter S, Lawrence CM, Rifkin DB and Barcellos-Hoff MH: Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res 166: 839-848, 2006.
5. Li C, Guo B, Bernabeu C and Kumar S: Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech 52: 437-449, 2001.
6. Barcellos-Hoff MH and Dix TA: Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10: 1077-1083, 1996.
7. Abate-Shen C and Shen MM: Molecular genetics of prostate cancer. Genes Dev 14: 2410-2434, 2000.
8. Kusunoki Y and Hayashi T: Long-lasting alterations of the immune system by ionizing radiation exposure: implications for disease development among atomic bomb survivors. Int J Radiat Biol 84: 1-14, 2008.
9. Bierie B and Moses HL: TGF-beta and cancer. Cytokine Growth Factor Rev 17: 29-40, 2006.
10. Rich J, Borton A and Wang X: Transforming growth factor-beta signaling in cancer. Microsc Res Tech 52: 363-373, 2001.
11. Teicher BA: Transforming growth factor-{beta} and the immune response to malignant disease. Clin Cancer Res 13: 6247-6251, 2007.
12. Walsh DA: Pathophysiological mechanisms of angiogenesis. Adv Clin Chem 44: 187-221, 2007.
13. Vaupel P and Mayer A: Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 12: 5-10, 2005.
14. Duque JLF, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E and Freeman MR: Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics 61: 401-408, 2006.
15. Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA and Stratford IJ: Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67: 84-90, 2007.
16. Jin P, Wang E, Provenzano M, Stroncek D and Marincola FM: Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit Rev Immunol 27: 437-448, 2007.
17. Bachmann MF and Oxenius A: Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 8: 1142-1148, 2007.
18. Salvemini D, Riley DP and Cuzzocrea S: SOD mimetics are coming of age. Nat Rev Drug Discov 1: 367-374, 2002.
19. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN, Feng QF, Kang SK, Spasojevic I, Samulski TV, Fridovich I, Dewhirst MW and Anscher MS: A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 33: 857-863, 2002.
20. Ferrer-Sueta G, Vitturi D, Batinic-Haberle I, Fridovich I, Goldstein S, Czapski G and Radi R: Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J Biol Chem 278: 27432-27438, 2003.
21. Spasojevic I, Batinic-Haberle I and Fridovich I: Nitrosylation of manganese (II) tetrakis(N-ethylpyridinium-2-yl) porphyrin: a simple and sensitive spectrophotometric assay for nitric oxide. Nitric Oxide 4: 526-533, 2000.
22. Shimizu K, Rajapakse N, Horiguchi T, Payne RM and Busija DW: Protective effect of a new nonpeptidyl mimetic of SOD, M40401, against focal cerebral ischemia in the rat. Brain Res 963: 8-14, 2003.
23. Haskins K, Bradley B, Powers K, Fadok V, Flores S, Ling X, Pugazhenthi S, Reusch J and Kench J: Oxidative stress in type 1 diabetes. Ann NY Acad Sci 1005: 43-54, 2003.
24. Kaul DK, Liu XD, Zhang X, Ma L, Hsia CJC and Nagel RL: Inhibition of sickle red cell adhesion and vasoocclusion in the microcirculation by antioxidants. Am J Physiol Heart Circ Physiol 291: H167-175, 2006.
25. Moeller BJ, Batinic-Haberle I, Spasojevic I, Rabbani ZN, Anscher MS, Vujaskovic Z and Dewhirst MW: A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. Int J Radiat Oncol Biol Phys 63: 545-552, 2005.
26. Gridley DS, Makinde AY, Luo X, Rizvi A, Crapo JD, Dewhirst MW, Moeller BJ, Pearlstein RD and Slater JM: Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res 27: 3101-3109, 2007.
27. Chang L-YL, Subramaniam M, Yoder BA, Day BJ, Ellison MC, Sunday ME and Crapo JD: A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med 167: 57-64, 2003.
28. Mackensen GB, Patel M, Sheng H, Calvi CL, Batinic-Haberle I, Day BJ, Liang LP, Fridovich I, Crapo JD, Pearlstein RD and Warner DS: Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J Neurosci 21: 4582-4592, 2001.
29. Lubbers NL, Polakowski JS, Crapo JD, Wegner CD and Cox BF: Preischemic and postischemic administration of AEOL10113 reduces infarct size in a rat model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 41: 714-719, 2003.
30. Thompson TC, Timme TL, Park SH, Yang G and Ren C: Mouse prostate reconstitution model system: a series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 43: 248-254, 2000.
31. Batinic-Haberle I, Spasojevic I, Hambright P, Benov L, Crumbliss AL and Fridovich I: Relationship among redox potentials, proton dissociation constants of pyrrolic nitrogens, and in vivo and in vitro superoxide dismutating activities of manganese(III) and iron(III) water-soluble porphyrins. Inorg Chem 38: 4011-4022, 1999.
32. Miller GM, Andres ML and Gridley DS: NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation. Int J Oncol 23: 1585-1592, 2003.
33. Varlotto J and Stevenson MA: Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63: 25-36, 2005.
34. Arlen PM and Gulley JL: Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs 6: 592-596, 2005.
35. Brill TH, Kubler HR, von Randenborgh H, Fend F, Pohla H, Breul J, Hartung R, Paul R, Schendel DJ and Gansbacher B: Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer - a phase I clinical trial. J Gene Med 9: 547-560, 2007.
36. Croci DO, Zacarias Pluck MF, Rico MJ, Matar P, Rabinovich GA and Scharovsky OG: Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56: 1687-1700, 2007.
37. Malmberg KJ: Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53: 879-892, 2004.
38. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M and Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007.
39. Scott GB, Meade JL and Cook GP. Profiling killers: unravelling the pathways of human natural killer cell function. Brief Funct Genomic Proteomic 7: 8-16, 2008.
40. Cerwenka A and Lanier LL: NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61: 335-343, 2003.
41. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A and Moretta L: Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31: 1076-1086, 2001.
42. Zinkernagel RM: What is missing in immunology to understand immunity? Nat Immunol 1: 181-185, 2000.
43. Lee JR: Reactive oxygen species play roles on B cell surface receptor CD40-mediated proximal and distal signaling events: effects of an antioxidant, N-acetyl-L-cysteine treatment. Mol Cell Biochem 252: 1-7, 2003.
44. Craxton A, Magaletti D, Ryan EJ and Clark EA: Macrophage-and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101: 4464-4471, 2003.
45. Shulga-Morskaya S, Dobles M, Walsh ME, Ng LG, MacKay F, Rao SP, Railed SL and Scott ML: B-cell-activating factor belonging to the TNF family acts through separate receptors to support B-cell survival and T-cell-independent antibody formation. J Immunol 173: 2331-2341, 2004.
46. Bergamin F, Vincent IE, Summerfield A and McCullough KC: Essential role of antigen-presenting cell-derived BAFF for antibody responses. Eur J Immunol 37: 3122-3130, 2007.
47. Rakhmilevich AL, Buhtoiarov IN, Malkovsky M and Sondel PM: CD40 ligation in vivo can induce T-cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother 57: 1151-1160, 2008.
48. Moon EY, Lee JH, Oh SY, Ryu SK, Kim HM, Kwak HS and Yoon WK: Reactive oxygen species augment B-cell-activating factor expression. Free Radic Biol Med 40: 2103-2111, 2006.
49. Tohyama Y, Takano T and Yamamura H: B-cell responses to oxidative stress. Curr Pharm Des 10: 835-839, 2004.
50. Liu J, Yoshida Y and Yamashita U: Suppressive effect of reactive oxygen species on CD40-induced B-cell activation. FEBS Letters 581: 5043-5049, 2007.
51. Storz P: Reactive oxygen species in tumor progression. Front Biosci 10: 1881-1896, 2005.
52. Wu WS: The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 25: 695-705, 2006.
53. Andarawewa KL, Paupert J, Pal A and Barcellos-Hoff MH: New rationales for using TGFbeta inhibitors in radiotherapy. Int J Radiat Biol 83: 803-811, 2007.
54. Bommireddy R and Doetschman T: TGFbeta1 and Treg cells: alliance for tolerance. Trends Mol Med 13: 492-501, 2007.